Dominik Alexander Hering

Headof Medical Physics

BoRad Gbr

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dominik Alexander Hering is the Head of Medical Physics at BoRad Gbr in Germany. His research focuses on the efficacy and safety of radiotherapy, with recent publications addressing dose constraints in cancer treatments, sustainability in oncology, and normal tissue complication probabilities. He has contributed significantly to understanding treatment outcomes in various cancers, including prostate cancer, Hodgkin lymphoma, and head and neck squamous cell carcinoma.

Articles (10)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Collaborators (3)

Michael Oertel

University of Münster

GERMANY

View details

Michael Fuchs

University of Cologne

GERMANY

View details

Moritz Wildgruber

University Hospital Regensburg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Dominik Alexander Hering

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Can the Dose Constraints Be Trusted? Actual Dose Exposure of Bladder and Rectum During Prostate Cancer Radiotherapy

Estimation of Mediastinal Toxicities after Radiotherapy for Hodgkin Lymphoma—A Normal Tissue Complication Analysis of the HD16/17 Trial by the German Hodgkin Study Group

Sustainability in radiation oncology: opportunities for enhancing patient care and reducing CO2 emissions in breast cancer radiotherapy at selected German centers

Involved-Site Radiation Therapy Enables Effective Disease Control in Parenchymal Low-Grade Primary Cerebral Lymphoma

DEGRO 2023 Abstractbuch

Dose-escalated re-irradiation improves outcome in locally recurrent head and neck cancer-Results of a large multicenter analysis

Efficacy of Multimodality Approach in Patients With Recurrent Head and Neck Squamous Cell Carcinoma

Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma

Radiotherapy in the GHSG HD 16 and HD 17 trials – quality assurance and dosimetric analysis for Hodgkin lymphoma in the modern era

Definition of an Normal Tissue Complication Probability Model for the Inner Ear in Definitive Radiochemotherapy of Nasopharynx Carcinoma

Collaborators (3)

Michael Oertel

Michael Fuchs

Moritz Wildgruber

Make your next move.